Interaction between growth hormone releasing factor (GRF) and somatostatin analogue (SMS 201-995) in normal subjects

M. Losa, O. A. Muller, S. Sobieszczyk, K. Von Werder

Research output: Contribution to journalArticle

Abstract

Continuous infusion or pulsatile administration of growth hormone releasing factors leads to decreasing GH levels and GH responses in normal subjects. We have given 50 μg GRF 1-44 i.v. four times in 2-hourly intervals to five normal subjects. After 1 week the same protocol was repeated after s.c. administration of 50 μg of the synthetic octapeptide somatostatin (SMS 201-995). The GH response to the same GRF doses was higher after the initial GRF pulse and blunted to the following GRF pulses (pulse I: 37:0 ± 11.2 ng/ml; Pulse II: 5.3 ± 1.2 ng/ml; pulse III: 5.9 ± 2.5 ng/ml; pulse IV: 5.9 ± 3.2 ng/ml; mean ± SE). When SMS 201-995 was given 60 min before pulsatile GRF administration, the GH secretion pattern was reversed (pulse I: 2.4 ± 0.7 ng/ml; pulse II: 2.0 ± 0.9 ng/ml; pulse III: 4.4 ± 2.1 ng/ml; pulse IV: 11.4 ± 3.6 ng/ml). Radioimmunoassayable GRF levels were not different before and after administration of SMS 201-995. The half time of disappearance was 8.6 ± 0.4 min before and 8.0 ± 0.5 min after SMS 201-995. Basal thyrotrophin and insulin levels, which remained constant over the 8 h period with GRF only, decreased significantly after SMS 201-995 administration. These findings are compatible with a limited releasable GH pool which is exhausted by chronic GRF stimulation but can be conserved by prior administration of the somatostatin analogue. Thus, when somatostatin bioactivity tapers off, there is recovery of GRF-stimulated GH secretion.

Original languageEnglish
Pages (from-to)715-720
Number of pages6
JournalClinical Endocrinology
Volume23
Issue number6
Publication statusPublished - 1985

Fingerprint

Growth Hormone-Releasing Hormone
Octreotide
Somatostatin
Thyrotropin
Insulin

ASJC Scopus subject areas

  • Endocrinology

Cite this

Interaction between growth hormone releasing factor (GRF) and somatostatin analogue (SMS 201-995) in normal subjects. / Losa, M.; Muller, O. A.; Sobieszczyk, S.; Von Werder, K.

In: Clinical Endocrinology, Vol. 23, No. 6, 1985, p. 715-720.

Research output: Contribution to journalArticle

@article{36013e2ee90d4641ba2a14a2b9cd2fbc,
title = "Interaction between growth hormone releasing factor (GRF) and somatostatin analogue (SMS 201-995) in normal subjects",
abstract = "Continuous infusion or pulsatile administration of growth hormone releasing factors leads to decreasing GH levels and GH responses in normal subjects. We have given 50 μg GRF 1-44 i.v. four times in 2-hourly intervals to five normal subjects. After 1 week the same protocol was repeated after s.c. administration of 50 μg of the synthetic octapeptide somatostatin (SMS 201-995). The GH response to the same GRF doses was higher after the initial GRF pulse and blunted to the following GRF pulses (pulse I: 37:0 ± 11.2 ng/ml; Pulse II: 5.3 ± 1.2 ng/ml; pulse III: 5.9 ± 2.5 ng/ml; pulse IV: 5.9 ± 3.2 ng/ml; mean ± SE). When SMS 201-995 was given 60 min before pulsatile GRF administration, the GH secretion pattern was reversed (pulse I: 2.4 ± 0.7 ng/ml; pulse II: 2.0 ± 0.9 ng/ml; pulse III: 4.4 ± 2.1 ng/ml; pulse IV: 11.4 ± 3.6 ng/ml). Radioimmunoassayable GRF levels were not different before and after administration of SMS 201-995. The half time of disappearance was 8.6 ± 0.4 min before and 8.0 ± 0.5 min after SMS 201-995. Basal thyrotrophin and insulin levels, which remained constant over the 8 h period with GRF only, decreased significantly after SMS 201-995 administration. These findings are compatible with a limited releasable GH pool which is exhausted by chronic GRF stimulation but can be conserved by prior administration of the somatostatin analogue. Thus, when somatostatin bioactivity tapers off, there is recovery of GRF-stimulated GH secretion.",
author = "M. Losa and Muller, {O. A.} and S. Sobieszczyk and {Von Werder}, K.",
year = "1985",
language = "English",
volume = "23",
pages = "715--720",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Interaction between growth hormone releasing factor (GRF) and somatostatin analogue (SMS 201-995) in normal subjects

AU - Losa, M.

AU - Muller, O. A.

AU - Sobieszczyk, S.

AU - Von Werder, K.

PY - 1985

Y1 - 1985

N2 - Continuous infusion or pulsatile administration of growth hormone releasing factors leads to decreasing GH levels and GH responses in normal subjects. We have given 50 μg GRF 1-44 i.v. four times in 2-hourly intervals to five normal subjects. After 1 week the same protocol was repeated after s.c. administration of 50 μg of the synthetic octapeptide somatostatin (SMS 201-995). The GH response to the same GRF doses was higher after the initial GRF pulse and blunted to the following GRF pulses (pulse I: 37:0 ± 11.2 ng/ml; Pulse II: 5.3 ± 1.2 ng/ml; pulse III: 5.9 ± 2.5 ng/ml; pulse IV: 5.9 ± 3.2 ng/ml; mean ± SE). When SMS 201-995 was given 60 min before pulsatile GRF administration, the GH secretion pattern was reversed (pulse I: 2.4 ± 0.7 ng/ml; pulse II: 2.0 ± 0.9 ng/ml; pulse III: 4.4 ± 2.1 ng/ml; pulse IV: 11.4 ± 3.6 ng/ml). Radioimmunoassayable GRF levels were not different before and after administration of SMS 201-995. The half time of disappearance was 8.6 ± 0.4 min before and 8.0 ± 0.5 min after SMS 201-995. Basal thyrotrophin and insulin levels, which remained constant over the 8 h period with GRF only, decreased significantly after SMS 201-995 administration. These findings are compatible with a limited releasable GH pool which is exhausted by chronic GRF stimulation but can be conserved by prior administration of the somatostatin analogue. Thus, when somatostatin bioactivity tapers off, there is recovery of GRF-stimulated GH secretion.

AB - Continuous infusion or pulsatile administration of growth hormone releasing factors leads to decreasing GH levels and GH responses in normal subjects. We have given 50 μg GRF 1-44 i.v. four times in 2-hourly intervals to five normal subjects. After 1 week the same protocol was repeated after s.c. administration of 50 μg of the synthetic octapeptide somatostatin (SMS 201-995). The GH response to the same GRF doses was higher after the initial GRF pulse and blunted to the following GRF pulses (pulse I: 37:0 ± 11.2 ng/ml; Pulse II: 5.3 ± 1.2 ng/ml; pulse III: 5.9 ± 2.5 ng/ml; pulse IV: 5.9 ± 3.2 ng/ml; mean ± SE). When SMS 201-995 was given 60 min before pulsatile GRF administration, the GH secretion pattern was reversed (pulse I: 2.4 ± 0.7 ng/ml; pulse II: 2.0 ± 0.9 ng/ml; pulse III: 4.4 ± 2.1 ng/ml; pulse IV: 11.4 ± 3.6 ng/ml). Radioimmunoassayable GRF levels were not different before and after administration of SMS 201-995. The half time of disappearance was 8.6 ± 0.4 min before and 8.0 ± 0.5 min after SMS 201-995. Basal thyrotrophin and insulin levels, which remained constant over the 8 h period with GRF only, decreased significantly after SMS 201-995 administration. These findings are compatible with a limited releasable GH pool which is exhausted by chronic GRF stimulation but can be conserved by prior administration of the somatostatin analogue. Thus, when somatostatin bioactivity tapers off, there is recovery of GRF-stimulated GH secretion.

UR - http://www.scopus.com/inward/record.url?scp=0022368433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022368433&partnerID=8YFLogxK

M3 - Article

C2 - 2869845

AN - SCOPUS:0022368433

VL - 23

SP - 715

EP - 720

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -